The injectables segment by diagnosis is estimated to lead the market growth during the forecast period.
According to a new market research study of “North America Non-Invasive Aesthetic Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Procedure, End-user and Country.” The North America non-invasive aesthetic treatment market is expected to reach US$ 8,085.74 million by 2028 from US$ 3,126.34 million in 2021; it is estimated to grow at a CAGR of 14.5% from 2021 to 2028. The report highlights trends prevailing in the North America non-invasive aesthetic treatment market and the factors driving market along with those that act as hindrances.
The North America non-invasive aesthetic treatment market based on the procedure was segmented into injectables, skin rejuvenation, and others. In 2020, the injectables segment held the largest share of the market, and same segment is expected to grow at the fastest rate during the coming years.
Non-invasive aesthetic treatments have gained popularity in the past few years due to advantages such as minimal downtime, no scars, low cost, and less complications. The popularity and acceptance of these procedures is mainly attributed to their non-invasiveness. Besides, it has been proved that the accuracy rate of minimally invasive surgeries is greater than that of open surgeries. Therefore, the advantages of minimally invasive procedures over conventional surgery - such as faster recovery, reduced pain, and shortened hospital stays, and greater efficiency rate - contribute to the non-invasive aesthetic treatment market growth. As per the American Society for Aesthetic Plastic Surgery (ASAPS), in 2018, ~3.8 million minimally invasive cosmetic operations were performed in the US in people with age 55 and above. The advancements in nonsurgical technologies and unveiling of new surgery options have made aesthetics accessible to people. For example, the advantages of laser procedures have attracted younger people to improve their skin conditions, modify body parts, and correct their physical posture. Therefore, rising acceptance of non-invasive aesthetic/cosmetic procedures is driving the growth of the North America non-invasive aesthetic treatment market. Several government initiatives are helping in creating awareness regarding non-invasive aesthetic procedures among people, which is also boosting the market growth.
North America is highly affected due to the COVID-19 outbreak pandemic. In the US, due to an increasing number of infected patients, healthcare professionals and leading organizations distract the flow of healthcare resources from research & development to primary care, which is slowing down the process of innovation. In addition, the COVID-19 pandemic is perplexing healthcare institutions in the region with unprecedented operational and clinical challenges with diagnostics and bed availability. Moreover, high priorities for the diagnosis and treatment of COVID-19 are leading to decline in non-invasive aesthetic treatment, which is restraining the growth of the North America non-invasive aesthetic treatment market up to certain extent.
The growth of the market is attributed to some key driving factors such as the increasing volume of funding activities for various research studies and other applications, and declining cost of sequencing procedures is expected to boost the sequencing reagents market. However, dearth of skilled professionals is expected to obstruct the growth of the market to a certain extent during the forecast years.
Galderma, Alma Lasers, Merz Pharma, Bausch Health Companies Inc. Cutera Inc. Revance Therapeutics Inc. Cynosure, AbbVie Inc. Candela Medical and Johnson and Johnson Services, Inc. are among the leading companies operating in the North America non-invasive aesthetic treatment market
According to a new market research study of “North America Non-Invasive Aesthetic Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Procedure, End-user and Country.” The North America non-invasive aesthetic treatment market is expected to reach US$ 8,085.74 million by 2028 from US$ 3,126.34 million in 2021; it is estimated to grow at a CAGR of 14.5% from 2021 to 2028. The report highlights trends prevailing in the North America non-invasive aesthetic treatment market and the factors driving market along with those that act as hindrances.
The North America non-invasive aesthetic treatment market based on the procedure was segmented into injectables, skin rejuvenation, and others. In 2020, the injectables segment held the largest share of the market, and same segment is expected to grow at the fastest rate during the coming years.
Non-invasive aesthetic treatments have gained popularity in the past few years due to advantages such as minimal downtime, no scars, low cost, and less complications. The popularity and acceptance of these procedures is mainly attributed to their non-invasiveness. Besides, it has been proved that the accuracy rate of minimally invasive surgeries is greater than that of open surgeries. Therefore, the advantages of minimally invasive procedures over conventional surgery - such as faster recovery, reduced pain, and shortened hospital stays, and greater efficiency rate - contribute to the non-invasive aesthetic treatment market growth. As per the American Society for Aesthetic Plastic Surgery (ASAPS), in 2018, ~3.8 million minimally invasive cosmetic operations were performed in the US in people with age 55 and above. The advancements in nonsurgical technologies and unveiling of new surgery options have made aesthetics accessible to people. For example, the advantages of laser procedures have attracted younger people to improve their skin conditions, modify body parts, and correct their physical posture. Therefore, rising acceptance of non-invasive aesthetic/cosmetic procedures is driving the growth of the North America non-invasive aesthetic treatment market. Several government initiatives are helping in creating awareness regarding non-invasive aesthetic procedures among people, which is also boosting the market growth.
North America is highly affected due to the COVID-19 outbreak pandemic. In the US, due to an increasing number of infected patients, healthcare professionals and leading organizations distract the flow of healthcare resources from research & development to primary care, which is slowing down the process of innovation. In addition, the COVID-19 pandemic is perplexing healthcare institutions in the region with unprecedented operational and clinical challenges with diagnostics and bed availability. Moreover, high priorities for the diagnosis and treatment of COVID-19 are leading to decline in non-invasive aesthetic treatment, which is restraining the growth of the North America non-invasive aesthetic treatment market up to certain extent.
The growth of the market is attributed to some key driving factors such as the increasing volume of funding activities for various research studies and other applications, and declining cost of sequencing procedures is expected to boost the sequencing reagents market. However, dearth of skilled professionals is expected to obstruct the growth of the market to a certain extent during the forecast years.
Galderma, Alma Lasers, Merz Pharma, Bausch Health Companies Inc. Cutera Inc. Revance Therapeutics Inc. Cynosure, AbbVie Inc. Candela Medical and Johnson and Johnson Services, Inc. are among the leading companies operating in the North America non-invasive aesthetic treatment market
Reasons to buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America non-invasive aesthetic treatment market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America non-invasive aesthetic treatment market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
Table of Contents
1. Introduction
3. Research Methodology
4. North America Non-invasive Aesthetic Treatment Market - Market Landscape
5. Non-Invasive Aesthetic Treatment Market - Key Market Dynamics
6. Non-invasive Aesthetic Treatment Market - Global Analysis
7. Non-invasive Aesthetic Treatment Market Analysis - By Procedure
8. Non-invasive Aesthetic Treatment Market Analysis - By End User
9. Non-invasive Aesthetic Treatment Market - North America Analysis
10. Impact Of COVID-19 Pandemic on North America Non-invasive Aesthetic Treatment Market
11. Non-invasive Aesthetic Market-Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Galderma
- Alma Lasers
- Merz Pharma
- Bausch Health Companies Inc.
- Cutera Inc.
- Revance Therapeutics Inc.
- Cynosure
- AbbVie Inc.
- Candela Medical
- Johnson and Johnson Services, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 148 |
Published | July 2021 |
Forecast Period | 2021 - 2028 |
Estimated Market Value ( USD | $ 3126.34 Million |
Forecasted Market Value ( USD | $ 8085.74 Million |
Compound Annual Growth Rate | 14.5% |
Regions Covered | North America |